OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, today announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology. There is currently no approved vaccine against HCMV.
SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01
SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses
OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Eddie Gray, MBA, as Chairman of its Board of Directors. Gray joins the Board as an independent director.
GENEVA--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform, have signed a commercial license agreement (CLA) to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV). Under the CLA, SpyBiotech will leverage Selexis’ proprietary SUREtechnology Platform™ to generate the stable, high-yield production cell lines vital to advancing SpyBiotech’s HCMV program to human clinical trials.
GENEVA--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform, have signed a commercial license agreement (CLA) to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV). Under the CLA, SpyBiotech will leverage Selexis’ proprietary SUREtechnology Platform™ to generate the stable, high-yield production cell lines vital to advancing SpyBiotech’s HCMV program to human clinical trials.
3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement with SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases.